Expert Analysis

Endocrine Therapy

Source: CCO Independent Conference Coverage of the CCO Independent Conference Coverage of the 2007 San Antonio Breast Cancer Symposium*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Endocrine Therapy

Faculty:

Harold J. Burstein, MD, PhD
Peter Ravdin, MD, PhD
Eric P. Winer, MD

CREDIT INFORMATION

Release Date: February 28, 2008

Expiration Date: February 27, 2009

Physicians: maximum of 1.25 AMA PRA Category 1 Credits™

Registered Nurses: 1.3 Nursing contact hours

Pharmacists: 1.3 contact hours (0.13 CEUs)

Status: The activity is not currently available for credit.

Learning Objectives

Upon completion of this activity, participants should be able to:

Explain the current use of tamoxifen in patients with breast cancer
Describe the advantages of selective estrogen receptor modulators vs aromatase inhibitors in the treatment of invasive breast cancer
Discuss the use of hormone therapies to treat patients with breast cancer
Identify solutions to mitigate bone loss in patients receiving endocrine therapy for breast cancer

Topics covered include:

Optimal Duration of Adjuvant Tamoxifen Therapy
Selective ER Modulators vs AIs for Adjuvant Therapy: 100-Month Results of the ATAC Trial
Joint Toxicity and Aromatase Inhibitors: Results From the ATAC Trial
The Impact of Alternating Hormonal Therapies on Development of Joint Symptoms
Risedronate Protection Against AI-Associated Bone Mineral Density Loss: Results of the Randomized IBIS-II Trial Bone Substudy
Zoledronic Acid for AI–Associated Bone Loss in Women Receiving Letrozole: The Z-FAST Study 36-Month Follow-up
Denosumab Therapy Preserves Bone Mineral Density in Women With Nonmetastatic Breast Cancer on AI Therapy
The Use of Neoadjuvant Endocrine Therapy
RAD001 Plus Letrozole as Neoadjuvant Therapy in Postmenopausal Women
Risk Stratification Based on CYP2D6 Genotype
CYP2D6 as a Predictor of Adherence to Tamoxifen Therapy

Disclaimer: The materials published on the Clinical Care Options Sites reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.